Skip to content

A Pilot Study of Telehealth Mindfulness-Based Cognitive Therapy for Depression in Parkinson's Disease.

Alejandro Interian, Rachael B Miller, Lauren M St Hill, Miriam Latorre, Arlene King, Kailyn M. Rodriguez, Sarah L Mann, Rachel S Kashan, Nadeeka N Dissanayaka, Roseanne D Dobkin

Journal of geriatric psychiatry and neurology March 2023 DOI: 10.1177/08919887221103579 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Feasibility trial (uncontrolled pre-post) Randomized Pilot study Peer reviewed
Sample size 15
Population Adults with Parkinson's disease and DSM-5 depressive disorders
Duration 9 sessions, with assessments at baseline, endpoint, and 1-month follow-up
Topics Depression Meditation
Keywords Parkinson's disease Mindfulness meditation Psychotherapy Telehealth
Key findings Telehealth MBCT-PD was reported as feasible and beneficial in 15 participants with Parkinson's disease and clinically significant depression: completion rates exceeded 85%, treatment satisfaction was high, and notable improvements were observed in depression, anxiety, and quality of life over the trial. The authors conclude the intervention shows promise and warrants evaluation in a randomized clinical trial with more diverse participants.

Abstract

Introduction: Parkinson's disease (PD) is characterized by high-rates of depression with limited evidence-based treatment options to improve mood.

Objective: To expand therapeutic options, we evaluated the feasibility and effect of a telehealth mindfulness-based cognitive therapy intervention adapted for PD (MBCT-PD) in a sample of participants with DSM-5 depressive disorders.

Methods: Fifteen participants with PD and clinically-significant depression completed 9 sessions of MBCT-PD. Depression, anxiety, and quality of life were evaluated at baseline, endpoint, and 1-month follow-up.

Results: Telehealth MBCT-PD was feasible and beneficial. Completion rates exceeded 85% and treatment satisfaction rates were high. Notable improvements were observed for depression, anxiety, and quality of life over the course of the trial.

Conclusion: Telehealth MBCT-PD shows promise and warrants further evaluation via randomized clinical trial with more diverse participants. Such research holds the potential to expand the range of therapeutic options for depression in PD, thereby setting the stage for personalized care.

Comparable studies

Other non-randomized and open-label trials on depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Patients with recurrent depression 2015 Open-label trial n = 17

Citations in the library

Explore topics